Lymphocytic infiltration and survival in rectal cancer - PubMed
Lymphocytic infiltration and survival in rectal cancer
J R Jass. J Clin Pathol. 1986 Jun.
Abstract
Lymphocytic infiltration was assessed semiquantitatively in 447 specimens of rectal cancer. Corrected five year survivals for pronounced, moderate, and little lymphocytic infiltration were 92%, 65% and 36%, respectively. Grading was shown to be reproducible in an intraobserver study (observed agreement 81%, expected agreement 34%, kappa coefficient 0.72). In the multivariate survival analysis of grade and stage related variables lymphocytic infiltration was the only grade related variable to be accepted within the prognostic model. This model also included the number of lymph node metastases and the extent of tumour spread. It is suggested that the conservation of the normal interactive traffic between epithelium and mucosa associated lymphoid tissue (MALT) signals a low grade growth. This is supported by the association between lymphocytic infiltration and the expression of secretory component by malignant epithelium.
Similar articles
-
The pathological grading and staging of rectal cancer.
Jass JR. Jass JR. Scand J Gastroenterol Suppl. 1988;149:21-38. doi: 10.3109/00365528809096953. Scand J Gastroenterol Suppl. 1988. PMID: 3201157
-
Feasibility of new prognostic classification for rectal cancer.
Dundas SA, Laing RW, O'Cathain A, Seddon I, Slater DN, Stephenson TJ, Underwood JC. Dundas SA, et al. J Clin Pathol. 1988 Dec;41(12):1273-6. doi: 10.1136/jcp.41.12.1273. J Clin Pathol. 1988. PMID: 3225328 Free PMC article.
-
The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases.
Jass JR, Atkin WS, Cuzick J, Bussey HJ, Morson BC, Northover JM, Todd IP. Jass JR, et al. Histopathology. 1986 May;10(5):437-59. doi: 10.1111/j.1365-2559.1986.tb02497.x. Histopathology. 1986. PMID: 3721406
-
Tumour 'budding' as an index to estimate the potential of aggressiveness in rectal cancer.
Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC. Ueno H, et al. Histopathology. 2002 Feb;40(2):127-32. doi: 10.1046/j.1365-2559.2002.01324.x. Histopathology. 2002. PMID: 11952856
-
[Histopathologic examination of rectal carcinoma].
Wolf HK, Simiantonaki N. Wolf HK, et al. Zentralbl Chir. 1999;124(5):408-12. Zentralbl Chir. 1999. PMID: 10420526 Review. German.
Cited by
-
Immune regulation and anti-cancer activity by lipid inflammatory mediators.
Khadge S, Sharp JG, McGuire TR, Thiele GM, Black P, DiRusso C, Cook L, Klassen LW, Talmadge JE. Khadge S, et al. Int Immunopharmacol. 2018 Dec;65:580-592. doi: 10.1016/j.intimp.2018.10.026. Epub 2018 Nov 14. Int Immunopharmacol. 2018. PMID: 30447537 Free PMC article. Review.
-
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients.
Zlobec I, Molinari F, Martin V, Mazzucchelli L, Saletti P, Trezzi R, De Dosso S, Vlajnic T, Frattini M, Lugli A. Zlobec I, et al. World J Gastroenterol. 2010 Oct 14;16(38):4823-31. doi: 10.3748/wjg.v16.i38.4823. World J Gastroenterol. 2010. PMID: 20939111 Free PMC article.
-
Mühlberger M, Janko C, Unterweger H, Friedrich RP, Friedrich B, Band J, Cebulla N, Alexiou C, Dudziak D, Lee G, Tietze R. Mühlberger M, et al. Int J Nanomedicine. 2019 Oct 24;14:8421-8432. doi: 10.2147/IJN.S218488. eCollection 2019. Int J Nanomedicine. 2019. PMID: 31749616 Free PMC article.
-
The pattern of cytokine gene expression in human colorectal carcinoma.
Csiszár A, Szentes T, Haraszti B, Balázs A, Petrányi GG, Pócsik E. Csiszár A, et al. Pathol Oncol Res. 2004;10(2):109-16. doi: 10.1007/BF02893465. Epub 2004 Jun 9. Pathol Oncol Res. 2004. PMID: 15188028
-
Immune Cells in Colorectal Cancer: Prognostic Relevance and Role of MSI.
Deschoolmeester V, Baay M, Lardon F, Pauwels P, Peeters M. Deschoolmeester V, et al. Cancer Microenviron. 2011 Dec;4(3):377-92. doi: 10.1007/s12307-011-0068-5. Epub 2011 May 27. Cancer Microenviron. 2011. PMID: 21618031 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources